Wen Yazhou

Dr. Wen Yazhou


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Journal of Affective Disorders
Verified
Journal Article
Closed access
MJMing Jiang
Ming Jiang
QLQianqian Li
Qianqian Li
MMMingjie Mao
Mingjie Mao
CXChenyang Xu
Chenyang Xu
RZRongrong Zhou
Rongrong Zhou
SFShanwu Feng
Shanwu Feng

27 June 2024 in International Journal of Surgery
Verified
Journal Article
Open access
WYWen Yazhou
Wen Yazhou
MMMingjie Mao
Mingjie Mao
MJMing Jiang
Ming Jiang
QLQiaoqiao Liu
Qiaoqiao Liu
QLQian Li
Qian Li
SFShanwu Feng
Shanwu Feng
Background: Postoperative depression has a profound impact on patients’ postoperative rehabilitation and overall quality of life. Preventing postoperative depression is of significant value because conventional antidepressants have a slow onset of action. Esketamine showed prompt and sustained antidepressant efficacy. Nevertheless, the safety and effectiveness of perioperative esketamine in preventing postoperative depression are still unknown. The purpose of this meta-analysis was to assess the safety and effectiveness of perioperative intravenous esketamine in relation to its ability to prevent postoperative depression. Materials and methods: Randomized controlled trials were searched in the following databases: Web of Science, Cochrane Central Registry of Controlled Trials, PubMed, and Embase. The primary outcome assessed is the postoperative depression scores. Postoperative pain ratings and adverse effects constituted secondary outcomes. Subgroup analyses were carried out on the basis of multiple variables, including the absence or presence of preoperative depression, the mode of esketamine administration, the dosage of esketamine, and the type of anesthesia. Results: A total of 16 studies encompassed 1161 patients who received esketamine intervention, whereas 1106 patients served as controls. Esketamine was efficacious in reducing postoperative depression scores when administered perioperatively, and the esketamine group maintained a lower postoperative depression score than the control group more than 4 weeks after surgery. Esketamine effectively alleviated postoperative pain scores without increasing the occurrence of postoperative nausea and vomiting, dizziness, drowsiness, nightmares, and dissociation. Conclusion: The administration of esketamine during the perioperative has the potential to decrease postoperative depression and pain scores without increasing the incidence of adverse effects.